52 withdrawn. 52 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 52 | Withdrawn 52 |
| Phase 2 | 9 | Withdrawn 9 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil Administration of investigation of Eurofarma drug, Administration of Comparator - Allergic Rhinitis | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-03-01 | 2025-12-18 | |
| Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray Dupilumab - Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS) | Phase 3 | Withdrawn | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2024-07-17 | 2024-07-25 | |
| A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis Upadacitinib, Placebo for Upadacitinib - Atopic Dermatitis, Sleep Disturbance | Phase 3 | Withdrawn | AbbVie | 2024-05-23 | 2024-09-19 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis CBP-201, Placebo - Atopic Dermatitis | Phase 3 | Withdrawn | Connect Biopharm LLC | 2022-12-01 | 2023-03-21 | |
| Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis JW-100, Eucrisa - Atopic Dermatitis | Phase 3 | Withdrawn | Applied Biology, Inc. | 2022-11-24 | 2022-12-19 | |
| Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis MAGNÓLIA NASAL GEL, MOMETASONE FUROATE - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2022-08-01 | 2022-08-05 | |
| Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference) - Bronchial Asthma | Phase 3 | Withdrawn | Aurobindo Pharma Ltd | 2022-04-01 | 2022-05-20 | |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil Upadacitinib, Placebo for Upadacitinib - Atopic Dermatitis (AD) | Phase 3 | Withdrawn | AbbVie | 2020-12-24 | 2021-04-08 | |
| The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus Ketamine - Status Asthmaticus | Phase 3 | Withdrawn | Augusta University | 2020-01-01 | 2024-02-06 | |
| Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis Budesonid 50mcg (Noex), Budesonid 50mcg (Busonid) - Rhinitis, Allergic, Perennial | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2019-10-08 | 2019-10-09 | |
| Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis CPM, Placebo - Allergic Rhinitis, Nasal Congestion | Phase 2 / Phase 3 | Withdrawn | Larkin Community Hospital | 2019-07-30 | 2023-10-16 | |
| Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis EMS Mometasone gel, Mometasone spray nasal - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2019-05-01 | 2020-11-04 | |
| Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis EMS Mometasone gel, Mometasone spray nasal - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2019-05-01 | 2020-11-04 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma Beclomethasone 800 µg per day, Placebo, Beclomethasone 400 µg per day - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma Placebo, 400 µg per day Beclomethasone, 200 µg per day Beclomethasone - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 |
Showing 20 of 52. Sign in to see all of them.
Asthma (21) · Dermatitis, Atopic (11) · Rhinitis, Allergic (7) · Eczema (4) · Dermatitis (3) · Genetic Diseases, Inborn (3) · Immune System Diseases (3) · Pruritus (3) · Angioedemas, Hereditary (2) · Asthma, Exercise-Induced (2) · Eosinophilic Esophagitis (2) · Exanthema (2) · Hypersensitivity, Immediate (2) · Motor Activity (2)
Immune System Diseases (49) · Hypersensitivity, Immediate (47) · Respiratory Tract Diseases (33) · Respiratory Hypersensitivity (32) · Bronchial Diseases (22) · Lung Diseases, Obstructive (21) · Lung Diseases (20) · Skin and Connective Tissue Diseases (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Otorhinolaryngologic Diseases (13) · Skin Diseases (13) · Nose Diseases (12) · Genetic Diseases, Inborn (10) · Rhinitis (10)
Albuterol (3) · Fluticasone (3) · Mometasone Furoate (3) · montelukast (3) · Beclomethasone (2) · Budesonide (2) · Exercise (2) · Formoterol Fumarate (2) · Metered Dose Inhalers (2) · upadacitinib (2) · AK002 (1) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Adrenergic beta-Agonists (1) · Chlorpheniramine (1)
Eurofarma Laboratorios S.A. (4) · EMS (3) · Fougera Pharmaceuticals Inc. (3) · AbbVie (2) · Adamis Pharmaceuticals Corporation (2) · Azidus Brasil (2) · GlaxoSmithKline (2) · Merz North America, Inc. (2) · Organon and Co (2) · AO GENERIUM (1) · Actavis Inc. (1) · Agentschap NL (1) · Allakos Inc. (1) · Allerderm (1) · Alung Technologies (1)
United States (14) · Brazil (6) · Canada (1) · Germany (1) · Netherlands (1) · Russia (1) · United Kingdom (1)
Angela C Kaplan (3) · Dennis Carlo (2) · Michael Kuligowski, MD, PhD, MBA (2) · Arine M Vlieger, MD, PhD (1) · Beverley Patterson, PhD (1) · Christopher Hull, MD (1) · Cory Dunnick, MD (1) · Craig Paterson, MD (1) · Daniel Fonseca, MD (1) · David Bernstein, MD (1) · Elliot Israel (1)
2017 (1), U10HL051823 (1), U10HL051831 (1), U10HL051834 (1), U10HL051843 (1), U10HL051845 (1), U10HL056443 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1), U10HL074208 (1), U10HL074212 (1), U10HL074218 (1), U10HL074225 (1), U10HL074227 (1)